Quarterly ResultMay 6, 2026, 06:37 AM
United Therapeutics Q1 Revenue $781.5M, Net Income $274.9M; $2B Buyback
AI Summary
United Therapeutics reported Q1 2026 financial results with total revenues decreasing 2% year-over-year to $781.5 million and net income falling 15% to $274.9 million, resulting in diluted EPS of $5.82. The company announced positive clinical trial results for ADVANCE OUTCOMES and TETON-1 studies and plans to develop ralinepag DPI. Additionally, the Board approved a $2.0 billion share repurchase program, with $1.5 billion already executed in Q1 2026.
Key Highlights
- Board approved a $2.0 billion share repurchase program, expiring March 9, 2027.
- Executed $1.5 billion in accelerated share repurchases in Q1 2026, receiving 2,164,459 shares.
- Total revenues decreased 2% year-over-year to $781.5 million in Q1 2026.
- Net income decreased 15% year-over-year to $274.9 million.
- Diluted EPS decreased 12% year-over-year to $5.82.
- Tyvaso DPI revenues increased 9% to $330.3 million.
- Nebulized Tyvaso revenues decreased 22% to $127.2 million.
- Orenitram revenues increased 12% to $135.6 million.